🏅 FDA Orphan Designation

Trogarzo

ibalizumab

Manufacturer: Theratechnologies Inc.

Indicated for:

Acute disseminated encephalomyelitis without anti-MOG antibodiesOrphanMendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency

FDA-Approved Indications (2)

Acute disseminated encephalomyelitis without anti-MOG antibodiesOrphan Designation

TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug re…

Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency

Population: heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen

Indications & Usage

1 INDICATIONS AND USAGE TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. TROGARZO, a CD4-directed post-attachment HIV-1 inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.

💙 Support Programs

View all →

Trogarzo

Theratechnologies Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.